Galderma at record high after FY sales outlook hike, H1 beat

Galderma AG

24/07/2025 08:20

** Shares in Galderma GALD.S rise around 7% to all-time high after the Swiss dermatology company raised its FY net sales guidance and posted H1 figures above expectations

** Galderma now expects FY net sales to grow between 12% and 14% at constant currency, compared to 10%-12% targeted previously

** Vontobel says Galderma started well into 2025 with H1 sales beating the broker's and consensus expectations

** "The over-delivery H1 sales has allowed the company to raise its FY sales guidance despite some potential further tariff impacts in some consumer product categories," it says

** The stock is at the top of Switzerland's mid-cap index .SMIM

 (Reporting by Ozan Ergenay)

 ((ozan.ergenay@thomsonreuters.com))